Cellular Therapeutics is partner in two of the three UK Advanced Therapy Treatment Centres
Cellular Therapeutics is delighted to be part of two of the three ATTCs recently set-up (iMATCH based in Manchester and the Midland/Wales ATTC linking Birmingham, Nottingham and Wales NHS centres). We are looking forward to working with expert partners to facilitate the development and delivery of cell therapies in the UK.
For a press release announcing iMATCH please visit this link.
For a press release announcing MW-ATTC please visit the following links from the Welsh Blood Service and The University of Birmingham.
For a press release announcing iMATCH please visit this link.
For a press release announcing MW-ATTC please visit the following links from the Welsh Blood Service and The University of Birmingham.
Robert Hawkins (CEO) talking at "Oncology at the Limits 2016"
Professor Robert Hawkins discussed T Cell Mediated Immunotherapies for Cancer at "Oncology at the Limits 2016"
Thursday 31st March - Saturday 2nd April 2016, The Royal College of Physicians, London, UK
Please go to the link to watch the talk
Thursday 31st March - Saturday 2nd April 2016, The Royal College of Physicians, London, UK
Please go to the link to watch the talk
Cellular Therapeutics is working with the Cell Therapy Catapult on WT1 engineered T cells
Cellular Therapeutics is delighted to announce a contract to manufacture a cell therapy for the Cell Therapy Catapult's WT1 Clinical programme.
Please go to the link for more details in the full press release.
Cellular Therapeutics is a partner in an EU funded project
CTL is pleased to announce its involvement in an exciting EU funded clinical research project - ATTACK.
CTL is a partner in the project which aims to complete two phase II clinical studies using autologous, genetically engineered immune cells (T Cells). The first to examine the activity of engineered T cells in oesophago-gastric cancer. The second to the second to undertake a randomised phase II study to determine whether an optimised cell production system developed by the partners improves the current clinical response rates in patients with metastatic melanoma.
More information will soon be available on the ATTACK website.
CTL is a partner in the project which aims to complete two phase II clinical studies using autologous, genetically engineered immune cells (T Cells). The first to examine the activity of engineered T cells in oesophago-gastric cancer. The second to the second to undertake a randomised phase II study to determine whether an optimised cell production system developed by the partners improves the current clinical response rates in patients with metastatic melanoma.
More information will soon be available on the ATTACK website.